Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

被引：0
|
作者：
Necchi, Andrea
Bedke, Jens
Galsky, Matt D.
Shore, Neal D.
Plimack, Elizabeth R.
Xylinas, Evanguelos
Jia, Calvin
Hennika, Tammy
Moreno, Blanca Homet
Witjes, Alfred Alfred
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] IRCCS San Raffaele Hosp & Sci Inst, Dept Med Oncol, Milan, Italy
[3] Eberhard Karls Univ Tubingen, Tubingen, Germany
[4] Icahn Sch Med Mt Sinai, New York, NY USA
[5] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[6] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Univ Paris Cite, Bichat Claude Bernard Hosp, AP HP, Paris, France
[8] Merck & Co Inc, Rahway, NJ USA
[9] Radboud Univ Nijmegen, Nijmegen, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS585
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303
    Necchi, A.
    Bedke, J.
    Galsky, M. D.
    Shore, N. D.
    Xylinas, E.
    Jia, C.
    Dubrovsky, L.
    Homet, Moreno B.
    Witjes, A. J.
    EUROPEAN UROLOGY, 2023, 83 : S751 - S751
  • [2] KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
    Necchi, Andrea
    Bedke, Jens
    Galsky, Matt D.
    Shore, Neal D.
    Xylinas, Evanguelos
    Jia, Calvin
    Dubrovsky, Leonid
    Moreno, Blanca Homet
    Witjes, J. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
    Galsky, Matt D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth R.
    Jia, Calvin
    Sbar, Eric
    Moreno, Blanca Homet
    Witjes, Johannes Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303
    Galsky, Matthew D.
    Hoimes, Christopher J.
    Necchi, Andrea
    Shore, Neal
    Witjes, J. Alfred
    Steinberg, Gary
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Sbar, Eric
    Jia, Xieyang
    Siefker-Radtke, Arlene
    FUTURE ONCOLOGY, 2021, 17 (24) : 3137 - 3150
  • [5] KEYNOTE-905/EV-303: A phase 3 study of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer
    Hennika, Tammy
    Galsky, Matthew D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth
    Jia, Calvin
    Moreno, Blanca Homet
    Witjes, J. Alfred
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 207 - 208
  • [6] Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
    Hoimes, Christopher J.
    Loriot, Yohann
    Bedke, Jens
    Nishiyama, Hiroyuki
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
    Galsky, Matt D.
    Necchi, Andrea
    Shore, Neal D.
    Witjes, Fred
    Nam, Kijoeng
    Sbar, Eric
    Moreno, Blanca Homet
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
    Hoimes, Christopher J.
    Bedke, Jens
    Loriot, Yohann
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)
    Galsky, M.
    Necchi, A.
    Shore, N. D.
    Witjes, F.
    Nam, K.
    Godwin, J. L.
    Frenkl, T. L.
    Plimack, E. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] AUO Perioperative Use of Pembrolizumab plus Enfortumab Vedotin in Muscle-invasive Bladder Carcinoma
    Rexer, H.
    Merseburger, A.
    UROLOGIE, 2023, 62 (11): : 1262 - 1263
12345